Microfluidic Chip for Genome Analysis

用于基因组分析的微流控芯片

基本信息

批准号：
8401300
负责人：
Heinz-Ulrich Guenter Weier
金额：
$ 23.5万
依托单位：
UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-08-07 至 2014-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8401300
关键词：
Affect Area Benign Biological Assay Biological Markers Biomedical Engineering Blood Breast Breast Cancer Cell Cancer Patient Carcinoma Cell Count Cell Cycle Stage Cell Line Cell Nucleus Cells Chromatin Chromosome abnormality Chromosomes, Human, Pair 12 Classification Clinical Clinical Research Competence Conceptus Cytogenetic Analysis Cytogenetics Cytoplasm Cytosol DNA DNA Probes DNA Sequence Rearrangement Detection Development Devices Diagnosis Diagnostic Differential Diagnosis Disease Embryo Epigenetic Process Feasibility Studies Fertilization in Vitro Fine-needle biopsy Fluorescent in Situ Hybridization Freezing Gene Amplification Gene Deletion Gene Expression Gene Expression Profiling Gene Rearrangement Generations Genes Genetic Genome Glass Harvest Human In Situ Individual Interphase Cell Investigation Karyotype Label Lesion Live Birth Location Longevity Malignant - descriptor Malignant neoplasm of thyroid Measures Mesenchymal Metaphase Methodology Methods MicroRNAs Microfluidics Molecular Profiling Numerical Chromosomal Abnormality Oocytes Patients Phenotype Placenta Positioning Attribute Post-Translational Protein Processing Prediction of Response to Therapy Pregnancy Premalignant Proto-Oncogenes Protocols documentation Puncture biopsy Radiation Reproduction Research Research Personnel Resolution Sampling Slide Specimen Stretching Structural Chromosomal Abnormality Supporting Cell Techniques Technology Testing Thick Thyroid Adenoma Time Tissue Sample Tissues Transcript Work anticancer research base cancer diagnosis cancer therapy clinical practice design disease diagnosis experience granulosa cell innovation malignant breast neoplasm meetings multidisciplinary neoplastic cell novel point of care prototype technology development tool tumor

项目摘要

DESCRIPTION (provided by applicant): Biomarkers for disease exist in a variety of forms such as numerical or structural chromosome aberrations, epigenetic factors or altered gene expression, abnormal levels of blood constituents or post-translational modifications. Often accurate diagnosis and prediction of response to therapy cannot rely on a single biomarker, but a combination of several, potentially very different types of markers. This multidisciplinary bioengineering project targets the development of a versatile, inexpensive technology platform termed 'disposable microfluidic chip' (dMFC). To support diagnostic efforts in assisted human reproduction and cancer research and therapy, this team of experienced investigators seeks to develop a dMFC capable of immobilizing individual cells in defined positions (Aim 1), interrogating multiple genetic loci for sensitive detection of numerical and structural chromosome aberrations in clinical samples (Aims 2-3) as well as the semi- quantitative analysis of gene transcripts or tumor-specific microRNAs (Aim 4). While this R21 project will investigate the feasibility of measuring multiple potential disease biomarkers including translocations, gene amplifications and expression of up to three tumor-specific microRNAs in small numbers of thyroid and breast cancer cells, the chip design can easily be modified to suit different applications such as noninvasive gene expression profiling in assisted human reproduction (ART) to predict oocyte competence and embryo survival. Thus, the successful completion of this feasibility study will equip us with a versatile prototype dMFC to develop more clinically oriented protocols in subsequent studies. PUBLIC HEALTH RELEVANCE: For accurate diagnosis, many situations require the assessment of not just one, but a combination of several different types of disease biomarkers. This multidisciplinary bioengineering project seeks to develop an inexpensive, versatile technology platform to detect and quantitate multiple biomarkers such as a combination of chromosomal alterations and aberrant gene expression in clinical samples.

描述（申请人提供）：疾病的生物标志物以多种形式存在，例如数值或结构性染色体畸变，表观遗传因素或基因表达改变，血液成分的异常水平或翻译后修饰。通常，准确的诊断和对治疗反应的预测不能依赖于单个生物标志物，而是几种可能非常不同类型的标记的组合。这个多学科的生物工程项目的目标是开发一种用途廉价的技术平台，称为“一次性微流体芯片”（DMFC）。为了支持在辅助人类繁殖和癌症研究和治疗方面的诊断工作，这个经验丰富的研究人员试图开发能够将单个细胞固定在定义位置的DMFC（AIM 1），询问多个遗传基因座，以敏感地检测数值和结构性染色体的临床样本中的数值和结构性染色体差异（目标2-3），以及针对2-3次的分析，并构成2-3次分析，并构成2-3次的分析。（目标4）。 While this R21 project will investigate the feasibility of measuring multiple potential disease biomarkers including translocations, gene amplifications and expression of up to three tumor-specific microRNAs in small numbers of thyroid and breast cancer cells, the chip design can easily be modified to suit different applications such as noninvasive gene expression profiling in assisted human reproduction (ART) to predict oocyte competence and embryo survival.因此，这项可行性研究的成功完成将使我们拥有多功能原型DMFC，以在随后的研究中开发更临床的方案。公共卫生相关性：为了进行准确的诊断，许多情况不仅需要评估一种，而且需要几种不同类型的疾病生物标志物的组合。这个多学科的生物工程项目旨在开发一个廉价的多功能技术平台，以检测和量化多种生物标志物，例如染色体改变和临床样品中异常基因表达的组合。